Boston Scientific Reports Strong Q1 Sales Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy BSX?
Source: PRnewswire
Boston Scientific's stock is up 5.17% in pre-market trading, crossing above its 5-day SMA, reflecting positive investor sentiment following the company's strong Q1 2026 earnings report.
The company reported net sales of $5.203 billion, an 11.6% year-over-year growth, and a significant profit increase with GAAP net income of $1.341 billion, translating to an EPS of $0.90. This performance indicates robust market demand and successful strategies across all business segments, reinforcing Boston Scientific's leadership in the medical technology sector.
With a projected full-year net sales growth of approximately 7.0% to 8.5% and adjusted EPS expectations between $3.34 and $3.41, the company's optimistic outlook is likely to attract further investor interest, contributing to the stock's upward movement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 58.450
Low
94.00
Averages
108.14
High
132.00
Current: 58.450
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Releases New Data on Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ PFA platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and potentially enhancing the company's leadership in the cardiac treatment market.
- Safety Validation: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of FARAPULSE™ technology and boosting physician confidence in its use.
- WATCHMAN™ Device Performance: The WATCHMAN FLX™ LAAC device achieved a 100% acute success rate in the ALIGN-AF study, with 90.6% of patients achieving complete left atrial appendage closure within an average of 66 days, demonstrating its efficacy and safety in atrial fibrillation patients, which may enhance its market acceptance.
- Long-term Efficacy Data: Five-year follow-up data from the ASAP-TOO trial revealed a lower ischemic stroke rate of 7.8% in patients using the WATCHMAN device compared to 11.4% in the control group, providing a new treatment option for atrial fibrillation patients and potentially driving further growth for the company in the cardiac field.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026, highlighting serious governance concerns.
- Disappointing Earnings Report: On February 4, 2026, Boston Scientific reported lower-than-expected sales in its electrophysiology division for Q4 2025 and issued fiscal year 2026 guidance that significantly missed analyst expectations, reflecting pressures from slower market growth and increased competition.
- Significant Stock Drop: Following the earnings report, Boston Scientific's stock plummeted by $16.12, or 17.6%, closing at $75.50 on February 4, 2026, indicating strong investor concerns regarding the company's future outlook.
- Legal Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, suggesting that this case could have broader legal and financial implications.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm for potential lead plaintiff appointment, highlighting serious concerns over the company's financial health.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management provided overly optimistic statements while concealing the true state of its U.S. EP segment's growth, resulting in a significant loss of investor confidence and a stark contrast between management's claims and market expectations.
- Performance Miss Impact: On February 4, 2026, Boston Scientific reported disappointing U.S. EP sales, leading to a net income miss and a dramatic stock price drop of approximately 17.6%, from $91.62 to $75.50 in a single day, directly affecting investor sentiment and market performance.
- Legal Action Deadline: Shareholders must register for the class action by May 4, 2026, as failure to do so may result in the loss of their right to claim, underscoring the importance of legal processes in protecting shareholder rights.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose qualified law firms with proven success in leadership roles to ensure they receive the best representation in the class action, avoiding firms that merely act as intermediaries.
See More
Jim Cramer's Insights on Various Stocks
- Joby Aviation Risk Assessment: Joby Aviation is deemed too risky, with analysts advising new investors to be cautious to avoid disappointment from potential stock price drops, which could hinder its ability to attract new investors.
- BillionToOne Potential: Despite the overall poor performance of diagnostic companies, BillionToOne is viewed as a potential winner, with analysts believing its future performance is promising, which may draw more investor interest in its stock.
- Boston Scientific Competitive Pressure: Boston Scientific faces intense competition, with analysts noting that its market position is under threat; however, there is still potential for a rebound, prompting investors to watch for a price bottom before deciding to buy.
- Rocket Lab Investment Opportunity: Rocket Lab is considered a speculative stock worth investing in, with analysts optimistic about its future performance, especially leading up to the SpaceX IPO, which could attract more speculative investments.
See More
Boston Scientific Executives Face Securities Class Action
- Lawsuit Background: Boston Scientific Corporation (NYSE: BSX) is facing a securities class action involving five senior executives for alleged fraud during the period from July 23, 2025, to February 3, 2026, with a significant stock price drop of 17.6% on February 4, 2026, resulting in a loss of $16.12 per share, severely impacting investor confidence.
- Executive Accountability: The lawsuit alleges that executives, including Chairman and CEO Michael F. Mahoney, made false statements in financial reports, claiming “exceptional” performance despite being aware of declining U.S. electrophysiology procedure volumes and competitive pressures, which could lead to increased legal liability.
- Legal Framework: Under Section 20(a) of the Securities Exchange Act of 1934, the complaint asserts that these executives had control over the contents of Boston Scientific's SEC filings and public statements, having received relevant information prior to release and failing to correct misleading information, potentially facing severe legal repercussions.
- Investor Impact: Due to the executives' misleading statements and undisclosed negative information, investors may incur significant losses, and the outcome of the lawsuit will directly affect Boston Scientific's market reputation and future financing capabilities, further exacerbating market concerns regarding its financial transparency.
See More
Boston Scientific Releases New Data on Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ PFA platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and potentially enhancing the company's leadership in the cardiac treatment market.
- Safety Validation: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of FARAPULSE™ technology and boosting physician confidence in its use.
- WATCHMAN™ Device Performance: The WATCHMAN FLX™ LAAC device achieved a 100% acute success rate in the ALIGN-AF study, with 90.6% of patients achieving complete left atrial appendage closure within an average of 66 days, demonstrating its efficacy and safety in atrial fibrillation patients, which may enhance its market acceptance.
- Long-term Efficacy Data: Five-year follow-up data from the ASAP-TOO trial revealed a lower ischemic stroke rate of 7.8% in patients using the WATCHMAN device compared to 11.4% in the control group, providing a new treatment option for atrial fibrillation patients and potentially driving further growth for the company in the cardiac field.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026, highlighting serious governance concerns.
- Disappointing Earnings Report: On February 4, 2026, Boston Scientific reported lower-than-expected sales in its electrophysiology division for Q4 2025 and issued fiscal year 2026 guidance that significantly missed analyst expectations, reflecting pressures from slower market growth and increased competition.
- Significant Stock Drop: Following the earnings report, Boston Scientific's stock plummeted by $16.12, or 17.6%, closing at $75.50 on February 4, 2026, indicating strong investor concerns regarding the company's future outlook.
- Legal Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, suggesting that this case could have broader legal and financial implications.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm for potential lead plaintiff appointment, highlighting serious concerns over the company's financial health.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management provided overly optimistic statements while concealing the true state of its U.S. EP segment's growth, resulting in a significant loss of investor confidence and a stark contrast between management's claims and market expectations.
- Performance Miss Impact: On February 4, 2026, Boston Scientific reported disappointing U.S. EP sales, leading to a net income miss and a dramatic stock price drop of approximately 17.6%, from $91.62 to $75.50 in a single day, directly affecting investor sentiment and market performance.
- Legal Action Deadline: Shareholders must register for the class action by May 4, 2026, as failure to do so may result in the loss of their right to claim, underscoring the importance of legal processes in protecting shareholder rights.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose qualified law firms with proven success in leadership roles to ensure they receive the best representation in the class action, avoiding firms that merely act as intermediaries.
See More
Jim Cramer's Insights on Various Stocks
- Joby Aviation Risk Assessment: Joby Aviation is deemed too risky, with analysts advising new investors to be cautious to avoid disappointment from potential stock price drops, which could hinder its ability to attract new investors.
- BillionToOne Potential: Despite the overall poor performance of diagnostic companies, BillionToOne is viewed as a potential winner, with analysts believing its future performance is promising, which may draw more investor interest in its stock.
- Boston Scientific Competitive Pressure: Boston Scientific faces intense competition, with analysts noting that its market position is under threat; however, there is still potential for a rebound, prompting investors to watch for a price bottom before deciding to buy.
- Rocket Lab Investment Opportunity: Rocket Lab is considered a speculative stock worth investing in, with analysts optimistic about its future performance, especially leading up to the SpaceX IPO, which could attract more speculative investments.
See More
Boston Scientific Executives Face Securities Class Action
- Lawsuit Background: Boston Scientific Corporation (NYSE: BSX) is facing a securities class action involving five senior executives for alleged fraud during the period from July 23, 2025, to February 3, 2026, with a significant stock price drop of 17.6% on February 4, 2026, resulting in a loss of $16.12 per share, severely impacting investor confidence.
- Executive Accountability: The lawsuit alleges that executives, including Chairman and CEO Michael F. Mahoney, made false statements in financial reports, claiming “exceptional” performance despite being aware of declining U.S. electrophysiology procedure volumes and competitive pressures, which could lead to increased legal liability.
- Legal Framework: Under Section 20(a) of the Securities Exchange Act of 1934, the complaint asserts that these executives had control over the contents of Boston Scientific's SEC filings and public statements, having received relevant information prior to release and failing to correct misleading information, potentially facing severe legal repercussions.
- Investor Impact: Due to the executives' misleading statements and undisclosed negative information, investors may incur significant losses, and the outcome of the lawsuit will directly affect Boston Scientific's market reputation and future financing capabilities, further exacerbating market concerns regarding its financial transparency.
See More
